Terumo ends Boston pact and goes direct with vascular device sales:
This article was originally published in Clinica
Executive Summary
Terumo Medical, the US arm of Japanese group Terumo, is to take on the sales and marketing of its interventional vascular products in the US and Latin America, terminating a 15-year distribution partnership with Boston Scientific as a result. Somerset, New Jersey-based Terumo Medical's interventional systems business has undergone a four-fold expansion of its direct sales force in line with the new strategy, which takes effect in April 2006. Terumo already uses its own sales team for its line of peripheral embolisation products, including Bead Block microspheres and Progreat microcatheters.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.